

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2014

DESPATCHED ON 11TH FEBRUARY 2014

Lab no.	DR17 Absent 1.4%			DR18 Absent 1.4%			DR13 Absent 1.4%			DR14 Not Assessed 36.6%			DR1404 Absent 2.8%			DR52 Not Assessed 36.6%			DQ9 Absent 1.4%				
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI		
9									DR14	L	< 2000				DR52	L	< 2000						
11																							
12									DR14	L	< 2000				DR52	L	< 2000						
14																							
15																							
19																							
20									DR14	L	< 2000				DR52	L	< 2000						
23																							
24																							
25																							
26																							
28																							
34																							
35																							
38									DR14	L	< 2000				DR52	L	< 2000						
39																							
41																							
42									DR14	L	< 2000				DR52	L	< 2000						
45									DR14	L					DR52	L							
48																							
51																							
54									DR14	L	2000-5000				DR52	L	2000-5000						
58																							
62																							
112									DR14	L	< 2000				DR52	L	< 2000						
114									DR14	L	< 2000				DR52	L	< 2000						
116																							
117									DR14	L	< 2000				DR52	L	< 2000						
119																							
120									DR14	L	< 2000				DR52	L	< 2000						
136																							
139																							
142																							
145																							
147																							
149															DR52	L	< 2000						
157									DR14	L	< 2000				DR52	L	< 2000						
159																							
162									DR14	L	< 2000				DR52	L	< 2000						
164									DR14	L					DR52	L							
165									DR14	F+L	< 2000				DR52	L	< 2000						
169																							
181																							
185									DR14	L	< 2000	DR1404	L	< 2000	DR52	L	< 2000						
186																							
190																							
193																							
194									DR14	L	< 2000				DR52	L	< 2000						
195																							
197	DR17	L	< 2000	DR18	L	< 2000	DR13	L	< 2000	DR14	L	< 2000								DQ9	L	< 2000	
204																							
206																							
209									DR14	L	< 2000				DR52	L	< 2000						
216									DR14	L	< 2000												
218															DR52	L	< 2000						
227									DR14	L	< 2000												
229																							
232									DR14	L	< 2000				DR52	L	< 2000						
235																							
238																							
243									DR14	L	> 5000				DR52	L	> 5000						
245																							
262									DR14	L	< 2000				DR52	L	< 2000						
267									DR14	L	< 2000	DR1404	L	< 2000	DR52	L	< 2000						
268																							
271																							
277									DR14	L	< 2000				DR52	L	< 2000						
284																							
293																							
297															DR52	L	< 2000						
303																							

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number	1	< 2000	1	< 2000	1	< 2000	26	< 2000	2	< 2000	26	< 2000	1	< 2000
Total	71	1	71	1	71	1	71	22	71	2	71	22	71	1
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		0		0		0		1		0		1		0
		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
		0		0		0		1		0		1		0

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2014

DESPATCHED ON 11TH FEBRUARY 2014

HLA specificity for assessment

Consensus **No antibodies detected**
% reported
Lab no.

- 9
- 11
- 12
- 14
- 15
- 19
- 20
- 23
- 24
- 25
- 26
- 28
- 34
- 35
- 38
- 39
- 41
- 42
- 45
- 48
- 51
- 54
- 58
- 62
- 112
- 114
- 116
- 117
- 119
- 120
- 136
- 139
- 142
- 145
- 147
- 149
- 157
- 159
- 162
- 164
- 165
- 169
- 181
- 185
- 186
- 190
- 193
- 194
- 195
- 197
- 204
- 206
- 209
- 216
- 218
- 227
- 229
- 232
- 235
- 238
- 243
- 245
- 262
- 267
- 268
- 271
- 277
- 284
- 293
- 297
- 303

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number
Total

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2014

DESPATCHED ON 11TH FEBRUARY 2014

Techniques used IgG	Sample Treatment IgG	Allele Specific Antibodies IgG	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative
Lab no.																		
9 L	No treatment		LS2A01	500	14600	96												
11 L			LS2A01	1000	-	-	LSM12	2.5 Ratio	10259	73.74								
12 L	EDTA		LS2A01	500	14084	105	LSM12	Ratio 5	9296	112								
14 L	No treatment		LSAII	1500	16665	64												
15 L	EDTA		LS2A01	1000	17460	35												
19 L	No treatment		LS2A01	1000	14766	60												
20 C+L	No treatment		LS2A01	500	13685	39												
23 L	No treatment		LS2A01	1000	15876	53.01												
24 L			LS2PRA	26-Sep	12444	59												
25 L	EDTA		LSAII	1500	20027	150	LS2A01	1000	15783	64								
26 L	No treatment		LS2A01	-	10177	51	LSM12	4	13776	126								
28 L			LS2A01	500	13187	55												
34 L	No treatment		LS2A01	500	14439	48												
35 L	No treatment																	
38 L	EDTA		LS2A01	-	10509	57	LSM12		11214	70								
39 L	No treatment		LS2A01	-	11571	76												
41 L	No treatment		LS2A01	2000	16275	60												
42 L	EDTA		LS2A01	-	9112	53	LSM12		6424	41								
45 L	EDTA																	
48 L	Heat inactivation																	
51 L	EDTA		LS2A01	200	13389	23	LSM12	2.74	9284	19								
54 L	No treatment		LSM12	350	12226	38												
58 L	No treatment		LMX	-	179.5	-	LSAII	1000	18013		LS2A01	1000	13975	46	LSM12	Ratio 2.5-3	16978	119
62 L	No treatment		LS2A01	2000	15182	63												
112 L	No treatment	DPB1*04:01	LSAII	1000	18938	215/156/785												
114 L	No treatment		LS2A01	1000	12819	67												
116 C+L	No treatment		LSM12	-	11415	56												
117 E+L	No treatment		LS2A01	500	12975	30												
119 L	No treatment		LS2A01	1000	16994	129	LSM12	1.5	15512	91								
120 I	No treatment		LS2A01	500	16450	60												
136 L	No treatment		LS2A01	1000	15487	46												
139 L	No treatment		LSM12	4	16428	84												
142 L	EDTA		LS2A01	1000	14175	57												
145 L	No treatment		LSM12	1.5/1.2	15984	121												
147 L	No treatment																	
149 L			LSAII	-	10000	72-308												
157 L	No treatment		LS2A01	1000	20000	85												
159 L	No treatment		LS2A01	1500	13556	67												
162 L	No treatment		LSM12	3	17095	66.44												
164 L			LS2PRA	2000	18057	264												
165 F+E+L	No treatment		LS2A01	-	15903	46												
169 L	No treatment		LS2A01	1000	5493	30												
181																		
185 C+L		DPB1*04:01	LM2	-	19299	67	LSAII		17375	574								
186 L			LSAII	-	17072	111	LS2A01		12656	61								
190 L	EDTA		LS2A01	1000	16884	91.44	LSM12	3	16669	47.38								
193 L	No treatment		LS2A01	2000	17129	41												
194 L	DTT																	
195 L	No treatment		LS2A01	1000	>500	<1500												
197 L																		
204 L	EDTA		LS2A01	1000	14586	44												
206 L	EDTA		LS2A01	1000	12686	40												
209			LS2PRA	500	17066	63	LS2A01	500	20679	84								
216 L			LS2PRA	40	8185	65												
218 L	Dilution, Heat inactivation		LM2	-	19212	-	LSAII		17087	-								
227 L	Dilution		LM2	1000	22710	104	LS2A01	1500	14261	59	LSM12	3.8	12168	81				
229 L	No treatment		LSAII	-	15806	-												
232 L	No treatment		LS2A01	-	12068	36												
235 L			LS2PRA	1000	9704	45												
238 L	No treatment		LM2	-	16014	63/59/95	LSAII		14706	154/101/377								
243 L	No Treatment		LS2A01	1000	16480	29	LSM12	3	15946	80								
245 L	No Treatment		LS2A01	+	10931	52												
262 L	No Treatment		LSAII	ADBCR>5	16171	189												
267 L	No Treatment		LM2	3	21134	65/58/101	LSAII	2+weak	19539	195/170/776								
268 L	No Treatment		LM2	1000	19987	91/90/144	LSAII	1500	16045	147/106/443								
271 L	No Treatment		LS2A01	2000	16523	54												
277 L	No Treatment		LS2A01	500	13937	46												
284 L	No Treatment		LS2A01	1000	14500	60	LSM12	3	10902	68								
293 L	No Treatment		LS2PRA	1000	13477	50												
297 L	No Treatment		LSAII	ADBCR>5	19283	614												
303 L	EDTA		LS2A01	1000	9448	59												

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2014

DESPATCHED ON 11TH FEBRUARY 2014

Techniques used	Sample Treatment	Allele Specific Antibodies	Luminex kit (lot)	Cut-off value	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)	Cut-off value	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)	Cut-off value	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)	Cut-off value	Control bead MFI Positive	Control bead MFI Negative
used IgG	IgG	IgG	IgG	IgG	Positive	Negative	IgG	IgG	Positive	Negative	IgG	IgG	Positive	Negative	IgG	IgG	Positive	Negative
9 L	No treatment		LS2A01	1000	13160	99												
11 L		DQA*5	LS2A01	1000	8853	119	LSM12											
12 L	EDTA	DQA1*05:01	LS2A01	500	13262	67	LSM12	2.5 Ratio	10518	40.65								
14 L	No treatment		LSAII	1500	16872	32		Ratio 5	9357	159								
15 L	EDTA	DP14	LS2A01	1000	18344	27												
19 L	No treatment	DQA1*05:03, 05:05, 06:01	LS2A01	1000	14312	66												
20 C+L	No treatment	DQA1*05:01, DPB1*14:01, 18:01	LS2A01	500	13993	57												
23 L	No treatment	DQA1*05:01	LS2A01	1000	16825	44.67												
24 L	EDTA	DPB1*14	LSAII	1500/4/5	18087	224	LS2PRA	1000	12587	66	LS2A01	1000	14711	39				
25 L	EDTA	DQA1*05:01, DPB1*11:01, 11:01, 14:01	LSAII	1500	17853	174	LS2A01	1000	14351	56								
26 L	No treatment		LS2A01	1000	1769	61	LSM12	4	12506	50								
28 L		DQA1*01, 05, 06, DP14	LS2A01	500	7233	40												
34 L	No treatment	DQA1*05:01	LS2A01	500	14157	36												
35 L	No treatment																	
38 L	EDTA		LS2A01	1200	11677	212	LSM12		12786	89								
39 L	No treatment	DQA1*05:03, 05:05, 06:01	LS2A01	900	7976	45												
41 L	No treatment	DQA1*05:01, DPB1*11, 14	LS2A01	2000	15495	240												
42 L	EDTA	DQA1*05:01	LS2A01				LSM12		7306	121								
45 L	EDTA		LS2A01	1500	16101	44												
48 L	Heat inactivation																	
51 L	EDTA	DQA1*05:01	LS2A01	850	13540	32												
54 L	No treatment	DQA*05	LS2A01	1000	15217	33	LSM12	350	13083	48								
58 L	No treatment		LMX		17398		LSAII	1000	19608		LS2A01	1000	13753	47	LSM12	Ratio 2.5-3	15967	55
62 L	No treatment		LS2A01	2000	15649	42												
112 L	No treatment	DQA1*01:01, 01:02, 01:03, 01:04, 03:01, 03:02, 04:01, 05:01, 06:01	LSAII	1000	20519	263/251/370												
L	No treatment	DQA1*01:03, 01:02, 01:01, 03:03, 03:02, 03:01, 05:03, 05:05, 06:01, 05:01, 01:04, 02:01	LS2A01	1000	13233	80												
114																		
116 C+L	No treatment	DQA1*05:01	LS2A01	1000	15259	33	LSM12		12705	60								
117 E+L	No treatment	DQA1*05:01, DP14	LS2A01	500	12895	18												
119 L		DQA1*05	LS2A01	1000	15362	149	LSM12	1.5	17972	28								
120 I	No treatment	DQA1*05:01, DP14	LS2A01	500	16596	44												
136 L	No treatment	DQB1*02:01/DQA1*05:01	LS2A01	1000	15854	53												
138 L	No treatment	DQA1*05:01	LS2A01	1000	17891	33	LSM12	4	17655	40								
142 L	EDTA		LS2A01	1000	13603	41												
145 L	No treatment		LS2A01	1000	8860	99	LSM12	1.5/1.2	14003	39								
147 L	No treatment	DQAAlpha5:03 (3688), 05:05 (3637), 06:01 (3319)	LS2A01	1500	7989	41.86	LSM12	>5	9908	80.5								
149 L		DQA1*01:01, 01:02, 01:03, 01:04, 03:01, 04:01, 06:01	LS2A01	1000	10000	72-308												
157 L	No treatment	DQA1*05:01	LS2A01	1000	18500	80												
159 L	No treatment	DQA1*05:01	LS2A01	1500	9226	98												
162 L	No treatment	DQA1*05:01	LS2A01	1000	16642	108.38	LSM12	3	1157	59.33								
164 L			LS2PRA	2000	15496	158	LS2A01	2000	22637	91								
165 F+E+L	No treatment		LS2A01	1400	14356	45												
169 L	No treatment	DQA1*01:03, 01:01, 01:02, 03:03, 03:02, 02:01, 05:05, 05:03, 06:01	LS2A01	1000	4850	99												
181 L	No treatment	DQA1*05:01 (<2000), DP14 (<2000)	LS2A01	500	11311	28.9												
185 C+L	No treatment	DQA1*01, 03, 04, 06	LSAII		21256	222	LSAII		17219	307								
186 L			LSAII		16701	111	LS2A01		11960	35								
190 L	EDTA	DQA4, 6, 7	LS2A01	1000	18694	35.13	LSM12	3	17058	17.02								
193 L	No treatment		LS2A01	2000	17123	24												
194 L	DTT		LS2A01	500	9308	45												
195 L	No treatment		LS2A01	1000	>500	<1500												
197 L	EDTA		LS2A01	1000	16163	33												
206 L	EDTA	DP14	LS2A01	1000	13930	64												
209		DQA1*05:01, DPB1*11, 05, 10, 14, 28, 03, 18	LS2PRA	500	17076	46	LS2A01	500	21487	92								
216 L	L	Dilution, Heat inactivation	LS2PRA	58	9127	160												
		DQB1*03:02(DQ8), 03:03 (DQ9), 04:01, 04:02, 05:01, 05:03, 06:01, 06:02, 06:03, 06:04, DRB1*01:01, 01:02, 01:03, 03:01/17, 03:02, 03:03/18, 04:01, 04:02, 04:03, 04:05, 05:01, 09:01, 10:01, 11:01, 11:04, 12:01, 13:01, 13:03, 14:01, 14:04, 15:01, 15:02, 16:01, 16:02, DRB3*01:01/DR52, 02:02/DR52, 03:01/DR52, DRB5*01:01/DR51, 02:02/DR51, DQA*01:01, 01:02, 01:03, 01:04, 03:01, 04:01	LM2		20072		LSAII			14622								
218																		
227 L	Dilution		LM2	1000	23693	386	LS2A01	1500	14438	58	LSM12	3.8	13363	34				
		DRB1*13:03, 03:03, 03:01, 16:02, 01:02, 01:03, 04:01, 04:02, 04:03, 04:05, 15:02, DRB3*03:01, 02:02, 01:01, DRB5*02:02, 01:01, DQB1*06:02, 06:03, 06:01, 04:02, 03:03, 03:02, 05:03, DQA1*01:02, 01:03, 01:04, 01:01, 04:01, 03:01	LSAII		11472	37												
229	L	No treatment	LS2PRA	1000	12438	54												
232	L		LSAII		16056	181/193/318												
235 L			LS2A01	1000	17086	34												
238 L	No treatment	DQA1*01:01, 01:02, 01:03, 02:01, 03:01, 03:02, 03:03, 05:01, 05:03, 05:05, 06:01	LS2A01															
243	No Treatment		LS2A01															
245 L	No Treatment	DQA1*05:01, DP14	LS2A01															
262	L	No Treatment	LSAII															
267		DQB1*03:01, 03:02, 03:03, 08:01, 09:01, 10:01, 12:01, 14:01; DQA1*01:01, 01:02, 01:03, 01:04, 03:01, 04:01, 06:01	LM2															
268 L	No Treatment		LM2	1000	21098	327/1406/682	LSAII	1500	15514	184/185/297								
271 L	No Treatment	DQ2 (DQA1*05:01)	LS2A01	2000	13548	24												
277 L	No Treatment	DQA1*05:01, DP18	LS2A01	500	9893	51												
284 L	No Treatment	DQA1*05	LS2A01	1000	15341	45	LSM12	3	11519	50								
293 L	No Treatment	DP5, 18	LS2PRA	1000	9658	26												
297 L	No Treatment		LSAII	ADBCR>5	19905	367												
303 L	EDTA	DQA1*05:01	LS2A01	1000	11756	55												

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION - 75% PRESENT

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2014

DESPATCHED ON 11TH FEBRUARY 2014

HLA specificity for assessment							Total	Total	%
	DR12	DR7	DR9	DR52	DQ2		Correct	Assessed	Correct
% reported	Present	Present	Present	Present	Present				
Lab no.	95.8%	100.0%	94.4%	87.3%	94.4%				
9	A	A	A	A	A		5	5	100.0%
11	A	A	A	A	A		5	5	100.0%
12	A	A	A	A	A		5	5	100.0%
14	A	A	A	A	A		5	5	100.0%
15	A	A	A	A	U		4	5	80.0%
19	U	A	U	U	U		1	5	20.0%
20	A	A	A	A	A		5	5	100.0%
23	A	A	A	A	A		5	5	100.0%
24	A	A	A	A	A		5	5	100.0%
25	A	A	A	A	A		5	5	100.0%
26	A	A	A	A	A		5	5	100.0%
28	A	A	A	A	A		5	5	100.0%
34	A	A	A	A	A		5	5	100.0%
35	A	A	A	A	A		5	5	100.0%
38	A	A	A	A	A		5	5	100.0%
39	A	A	A	A	A		5	5	100.0%
41	A	A	A	A	A		5	5	100.0%
42	A	A	A	A	A		5	5	100.0%
45	A	A	A	A	A		5	5	100.0%
48	A	A	A	A	A		5	5	100.0%
51	A	A	A	A	A		5	5	100.0%
54	A	A	A	A	A		5	5	100.0%
58	A	A	A	A	A		5	5	100.0%
62	A	A	A	A	A		5	5	100.0%
112	A	A	A	A	A		5	5	100.0%
114	A	A	A	A	A		5	5	100.0%
116	A	A	A	A	A		5	5	100.0%
117	A	A	A	A	A		5	5	100.0%
119	A	A	A	A	A		5	5	100.0%
120	A	A	A	A	A		5	5	100.0%
136	A	A	A	A	A		5	5	100.0%
139	A	A	A	A	A		5	5	100.0%
142	A	A	A	A	A		5	5	100.0%
145	A	A	A	A	A		5	5	100.0%
147	A	A	A	A	A		5	5	100.0%
149	A	A	A	A	A		5	5	100.0%
157	A	A	A	A	A		5	5	100.0%
159	A	A	A	A	A		5	5	100.0%
162	A	A	A	A	A		5	5	100.0%
164	A	A	A	A	A		5	5	100.0%
165	A	A	A	A	A		5	5	100.0%
169	U	A	U	U	A		2	5	40.0%
181	A	A	A	A	A		5	5	100.0%
185	A	A	A	A	A		5	5	100.0%
186	A	A	A	A	A		5	5	100.0%
190	A	A	A	A	A		5	5	100.0%
193	A	A	A	A	A		5	5	100.0%
194	A	A	A	A	A		5	5	100.0%
195	A	A	A	A	A		5	5	100.0%
197	A	A	A	U	A		4	5	80.0%
204	A	A	A	A	A		5	5	100.0%
206	A	A	A	A	A		5	5	100.0%
209	A	A	A	A	A		5	5	100.0%
216	A	A	U	U	U		2	5	40.0%
218	A	A	A	A	A		5	5	100.0%
227	A	A	A	A	A		5	5	100.0%
229	U	A	U	U	U		1	5	20.0%
232	A	A	A	A	A		5	5	100.0%
235	A	A	A	U	A		4	5	80.0%
238	A	A	A	A	A		5	5	100.0%
243	A	A	A	A	A		5	5	100.0%
245	A	A	A	U	A		4	5	80.0%
262	A	A	A	A	A		5	5	100.0%
267	A	A	A	A	A		5	5	100.0%
268	A	A	A	U	A		4	5	80.0%
271	A	A	A	A	A		5	5	100.0%
277	A	A	A	A	A		5	5	100.0%
284	A	A	A	A	A		5	5	100.0%
293	A	A	A	U	A		4	5	80.0%
297	A	A	A	A	A		5	5	100.0%
303	A	A	A	A	A		5	5	100.0%

A Acceptable
U Unacceptable

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION - 75% PRESENT

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2014

DESPATCHED ON 11TH FEBRUARY 2014

HLA specificity for assessment		
	Total Correct	Total Assessed
None		
% reported		
Lab no.		
9	0	0
11	0	0
12	0	0
14	0	0
15	0	0
19	0	0
20	0	0
23	0	0
24	0	0
25	0	0
26	0	0
28	0	0
34	0	0
35	0	0
38	0	0
39	0	0
41	0	0
42	0	0
45	0	0
48	0	0
51	0	0
54	0	0
58	0	0
62	0	0
112	0	0
114	0	0
116	0	0
117	0	0
119	0	0
120	0	0
136	0	0
139	0	0
142	0	0
145	0	0
147	0	0
149	0	0
157	0	0
159	0	0
162	0	0
164	0	0
165	0	0
169	0	0
181	0	0
185	0	0
186	0	0
190	0	0
193	0	0
194	0	0
195	0	0
197	0	0
204	0	0
206	0	0
209	0	0
216	0	0
218	0	0
227	0	0
229	0	0
232	0	0
235	0	0
238	0	0
243	0	0
245	0	0
262	0	0
267	0	0
268	0	0
271	0	0
277	0	0
284	0	0
293	0	0
297	0	0
303	0	0

A Acceptable
U Unacceptable

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION - 75% PRESENT

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/2014

DESPATCHED ON 11TH FEBRUARY 2014

HLA specificity for assessment													Total Correct	Total Assessed	% Correct		
% reported	DR15 Present	DR17 Present	DR18 Present	DR11 Present	DR12 Present	DR13 Present	DR14 Present	DR7 Present	DR8 Present	DR9 Present	DR52 Present	DQ2 Present					
Lab no.																	
9	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
11	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
12	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
14	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
15	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
19	U	A	A	A	A	A	A	A	A	A	A	A	A	11	12	91.7%	
20	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
23	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
24	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
25	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
26	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
28	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
34	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
35	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
38	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
39	U	A	A	A	A	A	A	A	A	A	A	A	A	11	12	91.7%	
41	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
42	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
45	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
48	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
51	U	A	A	A	A	A	A	A	A	A	A	A	A	11	12	91.7%	
54	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
58	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
62	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
112	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
114	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
116	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
117	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
119	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
120	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
136	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
139	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
142	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
145	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
147	U	A	A	A	A	A	A	A	A	A	A	A	A	11	12	91.7%	
149	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
157	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
159	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
162	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
164	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
165	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
169	U	A	A	A	A	A	A	A	A	U	A	A	A	10	12	83.3%	
181	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
185	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
186	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
190	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
193	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
194	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
195	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
197	U	A	A	A	A	A	A	U	A	U	A	A	A	9	12	75.0%	
204	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
206	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
209	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
216	U	A	A	A	A	A	A	A	A	U	U	U	U	8	12	66.7%	
218	U	A	A	A	A	A	A	A	A	A	A	A	A	11	12	91.7%	
227	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
229	U	U	U	A	A	A	A	A	A	U	U	A	A	7	12	58.3%	
232	U	A	A	A	A	A	A	A	A	U	A	A	A	10	12	83.3%	
235	U	A	A	A	A	A	A	U	A	U	A	A	A	9	12	75.0%	
238	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
243	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
245	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
262	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
267	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
268	A	A	A	A	A	A	A	A	A	A	U	A	A	11	12	91.7%	
271	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
277	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
284	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
293	U	U	U	U	A	A	A	A	U	U	U	A	A	5	12	41.7%	
297	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	
303	A	A	A	A	A	A	A	A	A	A	A	A	A	12	12	100.0%	

A Acceptable
U Unacceptable

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION - 75% PRESENT

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2014

DESPATCHED ON 11TH FEBRUARY 2014

HLA specificity for assessment		
	Total Correct	Total Assessed
None		
% reported		
Lab no.		
9	0	0
11	0	0
12	0	0
14	0	0
15	0	0
19	0	0
20	0	0
23	0	0
24	0	0
25	0	0
26	0	0
28	0	0
34	0	0
35	0	0
38	0	0
39	0	0
41	0	0
42	0	0
45	0	0
48	0	0
51	0	0
54	0	0
58	0	0
62	0	0
112	0	0
114	0	0
116	0	0
117	0	0
119	0	0
120	0	0
136	0	0
139	0	0
142	0	0
145	0	0
147	0	0
149	0	0
157	0	0
159	0	0
162	0	0
164	0	0
165	0	0
169	0	0
181	0	0
185	0	0
186	0	0
190	0	0
193	0	0
194	0	0
195	0	0
197	0	0
204	0	0
206	0	0
209	0	0
216	0	0
218	0	0
227	0	0
229	0	0
232	0	0
235	0	0
238	0	0
243	0	0
245	0	0
262	0	0
267	0	0
268	0	0
271	0	0
277	0	0
284	0	0
293	0	0
297	0	0
303	0	0

A Acceptable
U Unacceptable

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION - 95% ABSENT

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2014

DESPATCHED ON 11TH FEBRUARY 2014

HLA specificity for assessment		Total	Total	%	
	DR1	DQ5	Correct	Assessed	Correct
% reported	Absent	Absent			
Lab no.	1.4%	2.8%			
9	A	A	2	2	100.0%
11	A	A	2	2	100.0%
12	A	A	2	2	100.0%
14	A	A	2	2	100.0%
15	A	A	2	2	100.0%
19	A	A	2	2	100.0%
20	A	A	2	2	100.0%
23	A	A	2	2	100.0%
24	A	A	2	2	100.0%
25	A	A	2	2	100.0%
26	A	A	2	2	100.0%
28	A	A	2	2	100.0%
34	A	A	2	2	100.0%
35	A	A	2	2	100.0%
38	A	A	2	2	100.0%
39	A	A	2	2	100.0%
41	A	A	2	2	100.0%
42	A	A	2	2	100.0%
45	A	A	2	2	100.0%
48	A	A	2	2	100.0%
51	A	A	2	2	100.0%
54	A	A	2	2	100.0%
58	A	A	2	2	100.0%
62	A	A	2	2	100.0%
112	A	A	2	2	100.0%
114	A	A	2	2	100.0%
116	A	A	2	2	100.0%
117	A	A	2	2	100.0%
119	A	A	2	2	100.0%
120	A	A	2	2	100.0%
136	A	A	2	2	100.0%
139	A	A	2	2	100.0%
142	A	A	2	2	100.0%
145	A	A	2	2	100.0%
147	A	A	2	2	100.0%
149	A	A	2	2	100.0%
157	A	A	2	2	100.0%
159	A	A	2	2	100.0%
162	A	U	1	2	50.0%
164	A	A	2	2	100.0%
165	A	A	2	2	100.0%
169	A	A	2	2	100.0%
181	A	A	2	2	100.0%
185	A	A	2	2	100.0%
186	A	A	2	2	100.0%
190	A	A	2	2	100.0%
193	A	A	2	2	100.0%
194	A	A	2	2	100.0%
195	A	A	2	2	100.0%
197	A	A	2	2	100.0%
204	A	A	2	2	100.0%
206	A	A	2	2	100.0%
209	A	A	2	2	100.0%
216	A	A	2	2	100.0%
218	A	A	2	2	100.0%
227	A	A	2	2	100.0%
229	U	A	1	2	50.0%
232	A	A	2	2	100.0%
235	A	A	2	2	100.0%
238	A	A	2	2	100.0%
243	A	A	2	2	100.0%
245	A	A	2	2	100.0%
262	A	A	2	2	100.0%
267	A	A	2	2	100.0%
268	A	A	2	2	100.0%
271	A	A	2	2	100.0%
277	A	U	1	2	50.0%
284	A	A	2	2	100.0%
293	A	A	2	2	100.0%
297	A	A	2	2	100.0%
303	A	A	2	2	100.0%

A Acceptable
U Unacceptable

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION - 95% ABSENT

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2014

DESPATCHED ON 11TH FEBRUARY 2014

HLA specificity for assessment						Total	Total	%
% reported	DR17	DR18	DR13	DR1404	DQ9	Correct	Assessed	Correct
Lab no.	Absent	Absent	Absent	Absent	Absent			
	1.4%	1.4%	1.4%	2.8%	1.4%			
9	A	A	A	A	A	5	5	100.0%
11	A	A	A	A	A	5	5	100.0%
12	A	A	A	A	A	5	5	100.0%
14	A	A	A	A	A	5	5	100.0%
15	A	A	A	A	A	5	5	100.0%
19	A	A	A	A	A	5	5	100.0%
20	A	A	A	A	A	5	5	100.0%
23	A	A	A	A	A	5	5	100.0%
24	A	A	A	A	A	5	5	100.0%
25	A	A	A	A	A	5	5	100.0%
26	A	A	A	A	A	5	5	100.0%
28	A	A	A	A	A	5	5	100.0%
34	A	A	A	A	A	5	5	100.0%
35	A	A	A	A	A	5	5	100.0%
38	A	A	A	A	A	5	5	100.0%
39	A	A	A	A	A	5	5	100.0%
41	A	A	A	A	A	5	5	100.0%
42	A	A	A	A	A	5	5	100.0%
45	A	A	A	A	A	5	5	100.0%
48	A	A	A	A	A	5	5	100.0%
51	A	A	A	A	A	5	5	100.0%
54	A	A	A	A	A	5	5	100.0%
58	A	A	A	A	A	5	5	100.0%
62	A	A	A	A	A	5	5	100.0%
112	A	A	A	A	A	5	5	100.0%
114	A	A	A	A	A	5	5	100.0%
116	A	A	A	A	A	5	5	100.0%
117	A	A	A	A	A	5	5	100.0%
119	A	A	A	A	A	5	5	100.0%
120	A	A	A	A	A	5	5	100.0%
136	A	A	A	A	A	5	5	100.0%
139	A	A	A	A	A	5	5	100.0%
142	A	A	A	A	A	5	5	100.0%
145	A	A	A	A	A	5	5	100.0%
147	A	A	A	A	A	5	5	100.0%
149	A	A	A	A	A	5	5	100.0%
157	A	A	A	A	A	5	5	100.0%
159	A	A	A	A	A	5	5	100.0%
162	A	A	A	A	A	5	5	100.0%
164	A	A	A	A	A	5	5	100.0%
165	A	A	A	A	A	5	5	100.0%
169	A	A	A	A	A	5	5	100.0%
181	A	A	A	A	A	5	5	100.0%
185	A	A	A	U	A	4	5	80.0%
186	A	A	A	A	A	5	5	100.0%
190	A	A	A	A	A	5	5	100.0%
193	A	A	A	A	A	5	5	100.0%
194	A	A	A	A	A	5	5	100.0%
195	A	A	A	A	A	5	5	100.0%
197	U	U	U	A	U	1	5	20.0%
204	A	A	A	A	A	5	5	100.0%
206	A	A	A	A	A	5	5	100.0%
209	A	A	A	A	A	5	5	100.0%
216	A	A	A	A	A	5	5	100.0%
218	A	A	A	A	A	5	5	100.0%
227	A	A	A	A	A	5	5	100.0%
229	A	A	A	A	A	5	5	100.0%
232	A	A	A	A	A	5	5	100.0%
235	A	A	A	A	A	5	5	100.0%
238	A	A	A	A	A	5	5	100.0%
243	A	A	A	A	A	5	5	100.0%
245	A	A	A	A	A	5	5	100.0%
262	A	A	A	A	A	5	5	100.0%
267	A	A	A	U	A	4	5	80.0%
268	A	A	A	A	A	5	5	100.0%
271	A	A	A	A	A	5	5	100.0%
277	A	A	A	A	A	5	5	100.0%
284	A	A	A	A	A	5	5	100.0%
293	A	A	A	A	A	5	5	100.0%
297	A	A	A	A	A	5	5	100.0%
303	A	A	A	A	A	5	5	100.0%

A Acceptable
U Unacceptable

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION - 95% ABSENT

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/2014

DESPATCHED ON 11TH FEBRUARY 2014

HLA specificity for assessment					Total	Total	%
% reported	DR1 Absent 1.4%	DR51 Absent 1.4%	DR53 Absent 1.4%	DQ9 Absent 1.4%	Correct	Assessed	Correct
Lab no.							
9	A	A	A	A	4	4	100.0%
11	A	A	A	A	4	4	100.0%
12	A	A	A	A	4	4	100.0%
14	A	A	A	A	4	4	100.0%
15	A	A	A	A	4	4	100.0%
19	A	A	A	A	4	4	100.0%
20	A	A	A	A	4	4	100.0%
23	A	A	A	A	4	4	100.0%
24	A	A	A	A	4	4	100.0%
25	A	A	A	A	4	4	100.0%
26	A	A	A	A	4	4	100.0%
28	A	A	A	A	4	4	100.0%
34	A	A	A	A	4	4	100.0%
35	A	A	A	A	4	4	100.0%
38	A	A	A	A	4	4	100.0%
39	A	A	A	A	4	4	100.0%
41	A	A	A	A	4	4	100.0%
42	A	A	A	A	4	4	100.0%
45	A	A	A	A	4	4	100.0%
48	A	A	A	A	4	4	100.0%
51	A	A	A	A	4	4	100.0%
54	A	A	A	A	4	4	100.0%
58	A	A	A	A	4	4	100.0%
62	A	A	A	A	4	4	100.0%
112	A	A	A	A	4	4	100.0%
114	A	A	A	A	4	4	100.0%
116	A	A	A	A	4	4	100.0%
117	A	A	A	A	4	4	100.0%
119	A	A	A	A	4	4	100.0%
120	A	A	A	A	4	4	100.0%
136	A	A	A	A	4	4	100.0%
139	A	A	A	A	4	4	100.0%
142	A	A	A	A	4	4	100.0%
145	A	A	A	A	4	4	100.0%
147	A	A	A	A	4	4	100.0%
149	A	A	A	A	4	4	100.0%
157	A	A	A	A	4	4	100.0%
159	A	A	A	A	4	4	100.0%
162	A	A	A	A	4	4	100.0%
164	A	A	A	A	4	4	100.0%
165	A	A	A	A	4	4	100.0%
169	A	A	A	A	4	4	100.0%
181	A	A	A	A	4	4	100.0%
185	A	A	A	A	4	4	100.0%
186	A	A	A	A	4	4	100.0%
190	A	A	A	A	4	4	100.0%
193	A	A	A	A	4	4	100.0%
194	A	A	A	A	4	4	100.0%
195	A	A	A	A	4	4	100.0%
197	A	U	U	A	2	4	50.0%
204	A	A	A	A	4	4	100.0%
206	A	A	A	A	4	4	100.0%
209	A	A	A	A	4	4	100.0%
216	A	A	A	A	4	4	100.0%
218	A	A	A	A	4	4	100.0%
227	A	A	A	A	4	4	100.0%
229	U	A	A	A	3	4	75.0%
232	A	A	A	A	4	4	100.0%
235	A	A	A	A	4	4	100.0%
238	A	A	A	A	4	4	100.0%
243	A	A	A	A	4	4	100.0%
245	A	A	A	A	4	4	100.0%
262	A	A	A	A	4	4	100.0%
267	A	A	A	A	4	4	100.0%
268	A	A	A	A	4	4	100.0%
271	A	A	A	A	4	4	100.0%
277	A	A	A	A	4	4	100.0%
284	A	A	A	A	4	4	100.0%
293	A	A	A	U	3	4	75.0%
297	A	A	A	A	4	4	100.0%
303	A	A	A	A	4	4	100.0%

A Acceptable
U Unacceptable

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION - 95% ABSENT

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2014

DESPATCHED ON 11TH FEBRUARY 2014

HLA specificity for assessment		
	Total Correct	Total Assessed
None		
% reported		
Lab no.		
9	0	0
11	0	0
12	0	0
14	0	0
15	0	0
19	0	0
20	0	0
23	0	0
24	0	0
25	0	0
26	0	0
28	0	0
34	0	0
35	0	0
38	0	0
39	0	0
41	0	0
42	0	0
45	0	0
48	0	0
51	0	0
54	0	0
58	0	0
62	0	0
112	0	0
114	0	0
116	0	0
117	0	0
119	0	0
120	0	0
136	0	0
139	0	0
142	0	0
145	0	0
147	0	0
149	0	0
157	0	0
159	0	0
162	0	0
164	0	0
165	0	0
169	0	0
181	0	0
185	0	0
186	0	0
190	0	0
193	0	0
194	0	0
195	0	0
197	0	0
204	0	0
206	0	0
209	0	0
216	0	0
218	0	0
227	0	0
229	0	0
232	0	0
235	0	0
238	0	0
243	0	0
245	0	0
262	0	0
267	0	0
268	0	0
271	0	0
277	0	0
284	0	0
293	0	0
297	0	0
303	0	0

A Acceptable
U Unacceptable

UK NEQAS FOR H&I SCHEME 3 - HLA ANTIBODY IDENTIFICATION - 95% ABSENT

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2014

DESPATCHED ON 11TH FEBRUARY 2014

HLA specificity for assessment		Total	Total	%
DR7		Correct	Assessed	Correct
% reported	Absent			
Lab no.	1.4%			
9	A	1	1	100.0%
11	A	1	1	100.0%
12	U	0	1	0.0%
14	A	1	1	100.0%
15	A	1	1	100.0%
19	A	1	1	100.0%
20	A	1	1	100.0%
23	A	1	1	100.0%
24	A	1	1	100.0%
25	A	1	1	100.0%
26	A	1	1	100.0%
28	A	1	1	100.0%
34	A	1	1	100.0%
35	A	1	1	100.0%
38	A	1	1	100.0%
39	A	1	1	100.0%
41	A	1	1	100.0%
42	A	1	1	100.0%
45	A	1	1	100.0%
48	A	1	1	100.0%
51	A	1	1	100.0%
54	A	1	1	100.0%
58	A	1	1	100.0%
62	A	1	1	100.0%
112	A	1	1	100.0%
114	A	1	1	100.0%
116	A	1	1	100.0%
117	A	1	1	100.0%
119	A	1	1	100.0%
120	A	1	1	100.0%
136	A	1	1	100.0%
139	A	1	1	100.0%
142	A	1	1	100.0%
145	A	1	1	100.0%
147	A	1	1	100.0%
149	A	1	1	100.0%
157	A	1	1	100.0%
159	A	1	1	100.0%
162	A	1	1	100.0%
164	A	1	1	100.0%
165	A	1	1	100.0%
169	A	1	1	100.0%
181	A	1	1	100.0%
185	A	1	1	100.0%
186	A	1	1	100.0%
190	A	1	1	100.0%
193	A	1	1	100.0%
194	A	1	1	100.0%
195	A	1	1	100.0%
197	A	1	1	100.0%
204	A	1	1	100.0%
206	A	1	1	100.0%
209	A	1	1	100.0%
216	A	1	1	100.0%
218	A	1	1	100.0%
227	A	1	1	100.0%
229	A	1	1	100.0%
232	A	1	1	100.0%
235	A	1	1	100.0%
238	A	1	1	100.0%
243	A	1	1	100.0%
245	A	1	1	100.0%
262	A	1	1	100.0%
267	A	1	1	100.0%
268	A	1	1	100.0%
271	A	1	1	100.0%
277	A	1	1	100.0%
284	A	1	1	100.0%
293	A	1	1	100.0%
297	A	1	1	100.0%
303	A	1	1	100.0%

A Acceptable
U Unacceptable